

1
2
3 UNITED STATES DISTRICT COURT
4 FOR THE NORTHERN DISTRICT OF CALIFORNIA
5 OAKLAND DIVISION
6

7 LARRY J. DOUGLAS, et al.,

8 Plaintiffs,

9 vs.

10 BRISTOL-MYERS SQUIBB COMPANY,
11 MCKESSON CORPORATION, and DOES 1
to 100,

12 Defendants.
13

Case No: C 13-2331 SBA

**ORDER GRANTING
MOTION TO STAY**

Docket 9

14 The parties are presently before the Court on Bristol-Myers Squibb Company's
15 ("BMS") motion to stay pending transfer to the Plavix® MDL. Dkt. 9. Plaintiffs oppose
16 the motion. Dkt. 13. Having read and considered the papers filed in connection with this
17 matter and being fully informed, the Court hereby GRANTS BMS's motion to stay, for the
18 reasons stated below. The Court, in its discretion, finds this matter suitable for resolution
19 without oral argument. See Fed.R.Civ.P. 78(b); N.D. Cal. Civ. L.R. 7-1(b).

20 **I. BACKGROUND**

21 On April 22, 2013, Plaintiffs commenced the instant action against Defendants BMS
22 and McKesson Corporation (collectively "Defendants") in the Superior Court of California,
23 County of San Francisco, alleging injuries arising out of the use of the prescription drug
24 Plavix®. Compl., Dkt. 1. On May 22, 2013, BMS removed the action to this Court based
25 on diversity jurisdiction, 28 U.S.C. § 1332(a). See Notice of Removal, Dkt. 1.

26 Due to the number of Plavix® products liability actions filed, the Judicial Panel on
27 Multidistrict Litigation ("MDL Panel") established an MDL court in the United States
28 District Court for the District of New Jersey. See In re Plavix Mktg., Sales Practices &

1 Prods. Liab. Litig. (No. II), MDL No. 2418 ("Plavix® MDL"). See Dkt. 9-1. On June 7,
2 2013, the MDL Panel conditionally transferred this case to the MDL court. See Dkt. 17 at
3 4. The issue of whether this action will be transferred to the Plavix® MDL is currently
4 pending before the MDL Panel.

5 **II. DISCUSSION**

6 A district court has the inherent power to stay proceedings. "[T]he power to stay
7 proceedings is incidental to the power inherent in every court to control the disposition of
8 the causes on its docket with economy of time and effort for itself, for counsel, and for
9 litigants." Landis v. N. Am. Co., 299 U.S. 248, 254 (1936). A district court's decision to
10 grant or deny a stay is a matter of discretion. Dependable Highway Express, Inc. v.
11 Navigators Ins. Co., 498 F.3d 1059, 1066 (9th Cir. 2007). In determining whether to stay
12 proceedings pending a motion before the MDL Panel, the factors to consider include: (1)
13 conserving judicial resources and avoiding duplicative litigation; (2) hardship and inequity
14 to the moving party if the action is not stayed; and (3) potential prejudice to the non-
15 moving party. In re iPhone Application Litigation, 2011 WL 2149102, at *2 (N.D. Cal.
16 2011); see also Rivers v. Walt Disney Co., 980 F.Supp. 1358, 1360 (C.D. Cal. 1997).

17 The Court finds that the above-referenced factors weigh in favor of a stay. First,
18 there is no evidence that Plaintiffs will be prejudiced or inconvenienced by a stay. If this
19 case is transferred to the Plavix® MDL, Plaintiffs can present their motion to remand to the
20 MDL court. On the other hand, if the case is not transferred, this Court will resolve
21 Plaintiffs' motion to remand. Furthermore, the MDL Panel has conditionally transferred
22 this matter to the Plavix® MDL and it is unlikely that a stay of this action will last long.
23 The MDL Panel recently issued an order transferring sixteen similar cases from this district
24 to the Plavix® MDL, including an essentially identical case assigned to the undersigned,
25 Arenberg, et al. v. Bristol-Meyers Squibb Co., et al., C 12-06207 SBA. See Case No. C 12-
26 06207 SBA, Dkt. 31 ("Transfer Order"); see also Dkt. 15-1 (same). Second, BMS may
27 suffer hardship and inequity if a stay is not imposed. If this Court prematurely adjudicates
28 Plaintiffs' motion to remand, BMS may be forced to re-litigate issues before the MDL Panel

1 or in state court. See Arnold v. Bristol-Myers Squibb Co., C 12-6426 TEH (N.D. Cal. Apr.
2 3, 2013); Gibson v. Bristol-Myers Squibb Co., 2013 WL 2081964, at *1 (N.D. Cal. May
3 14, 2013) (Armstrong, J.).

4 Finally, a stay would promote judicial economy and uniformity. As noted, the MDL
5 Panel recently issued an order transferring sixteen of this district's Plavix® actions to the
6 Plavix® MDL, finding that the cases involve common questions of fact with actions
7 previously transferred to the MDL court, and concluding that "transfer will serve the
8 convenience of the parties and witnesses and promote the just and efficient conduct of the
9 litigation." See Transfer Order at 2 (noting that transfer is warranted for the reasons set out
10 in the original order directing centralization,¹ which states that "[c]entralization will
11 eliminate duplicative discovery, prevent inconsistent pretrial rulings, . . . and conserve the
12 resources of the parties, their counsel, and the judiciary."). There are also numerous
13 motions to remand pending before various judges of this district in other Plavix® actions
14 awaiting transfer to the Plavix® MDL. In light of the foregoing, the Court finds that
15 staying the instant action will avoid the possibility of inconsistent results and will conserve
16 judicial resources by avoiding the needless duplication of work in the event this case is
17 transferred. Accordingly, BMS's motion to stay is GRANTED.²

18 **III. CONCLUSION**

19 For the reasons stated above, IT IS HEREBY ORDERED THAT:

20 1. BMS's motion to stay is GRANTED. This action is STAYED until the
21 pending conditional transfer matter is resolved by the MDL Panel. The parties shall inform
22 the Court within seven (7) days from the date this matter is resolved.

23
24 ¹ See In re Plavix Mktg., Sales Practices & Prods. Liab. Litig. (No. II), MDL No. 2418, --- F.Supp.2d ----, 2013 WL 565971, at * 2 (J.P.M.L. 2013).

25 ² This Court joins other courts in this district that have granted motions to stay in
26 similar cases. See, e.g., Jones v. Bristol-Myers Squibb Co., 2013 WL 3388659 (N.D. Cal.,
27 July 8, 2013); Addison v. Bristol-Myers Squibb Co., 2013 WL 3187859 (N.D. Cal., June
28 21, 2013); Gibson, 2013 WL 2081964; Arenberg, C 12-06207 SBA; Kinney v. Bristol-Myers Squibb Co., C 12-4477 EMC (N.D. Cal. Apr. 12, 2013); Arnold, C 12-6426 TEH; Vanny v. Bristol-Myers Squibb Co., C 12-05752 SI (N.D. Cal. Mar. 25, 2013); Aiken v. Bristol-Myers Squibb Co., C 12-05208 RS (N.D. Cal. Mar. 14, 2013).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

2. The hearing scheduled for August 6, 2013 is VACATED.

3. This Order terminates Docket 9.

IT IS SO ORDERED.

Dated: 8/5/13


SAUNDRA BROWN ARMSTRONG
United States District Judge